ABBOTT PARK, Ill., Aug. 28 /PRNewswire-FirstCall/ -- Abbott will present results of its SPIRIT II clinical trial of the XIENCE(TM) V Everolimus Eluting Coronary Stent System at the World Congress of Cardiology (WCC) meeting in Barcelona, Spain, on Sept. 5. On that day at 6 a.m. Central time (7 a.m. Eastern time), Abbott will host a conference call with the investment community and the media to discuss the findings. Additionally, the principal investigator of the trial will discuss the results in a press conference and scientific program at the Fira Gran Via M2 on site at WCC, a joint meeting of the European Society of Cardiology and the World Heart Federation.
SPIRIT II is a 300-patient randomized clinical non-inferiority trial evaluating XIENCE V versus the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System.
Abbott’s schedule of WCC activities on Sept. 5 include:
Conference Call/Webcast
Abbott will host a live webcast to discuss SPIRIT II results at 6 a.m. Central time (7 a.m. Eastern time) or 1 p.m. Central European Summer Time (CEST). Participating on the call are Richard A. Gonzalez, president and chief operating officer, Abbott; John B. Thomas, vice president of Investor Relations, Abbott; John M. Capek, Ph.D., president of Cardiac Therapies, Abbott Vascular; and Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and principal investigator of the SPIRIT II clinical trial. The webcast will be accessible through Abbott’s Investor Relations Web site at http://www.abbottinvestor.com .
WCC Press Conference (on site media only)
Professor Serruys will discuss six-month data from the SPIRIT II clinical trial in WCC’s “Hotline II press conference” from 7:15-8:15 a.m. CEST (12:15-1:15 a.m. Central time, 1:15-2:15 a.m. Eastern time) in the Press Conference Room at WCC.
Presentations of SPIRIT II Clinical Trial Results
Professor Serruys will present six-month data from the SPIRIT II clinical trial during WCC’s “Hot Topics Session” of the scientific program, which will take place from 11 a.m.-12:30 p.m. CEST (4-5:30 a.m. Central time, 5-6:30 a.m. Eastern time) in room Barcelona (Zone 1).
Ashok Seth, M.D., chairman & chief cardiologist, Max Devki Devi Heart and Vascular Institute New Delhi, will present “SPIRIT II Study: A clinical evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the treatment of patients with de novo, native coronary artery lesions: Pharmacokinetic substudy,” at WCC’s “Poster session 6: DES Trials and Registries.” The session is being held in room Posters (Zone 2) from 2:30-6 p.m. CEST (7:30-11 a.m. Central time, 8:30 a.m. - noon Eastern time).
About the SPIRIT Family of Trials
The SPIRIT FIRST study of the XIENCE V System, which supported CE Mark approval, showed positive results through two years for patients with de novo native coronary artery lesions. SPIRIT II and SPIRIT III are large-scale pivotal clinical trials comparing XIENCE V to the TAXUS(R) Express 2(TM) Paclitaxel Eluting Coronary Stent System. SPIRIT IV, which recently enrolled its first patient, will evaluate the safety and efficacy of the XIENCE V Stent System for the treatment of coronary artery disease in a more complex patient population.
About Abbott Vascular’s Drug Eluting Stent Program
Abbott Vascular’s drug eluting stent program is comprised of two flagship products: the XIENCE V Everolimus Eluting Coronary Stent System, which received CE Mark approval earlier this year, and the ZoMaxx(TM) Drug-Eluting Coronary Stent System. Both systems include advanced stent platforms and controlled release of a drug from the -olimus class. XIENCE V utilizes the drug everolimus and the highly deliverable and proven MULTI-LINK VISION(R) coronary stent platform. Everolimus has been shown to reduce tissue proliferation in the coronary vessels following stent implantation. XIENCE V is currently an investigational device in the United States and Japan. The ZoMaxx drug-eluting stent system features zotarolimus, a compound developed specifically for use on drug-eluting stents, and Abbott’s TriMaxx(TM) stainless steel and tantalum stent platform, which has received CE Mark approval and is available for sale in Europe and select other geographies. ZoMaxx is an investigational device in the United States.
Abbott Vascular is also developing bioabsorbable drug eluting stents as well as drug eluting stents that utilize a combination of drugs.
About Abbott Vascular
Abbott Vascular, a division of Abbott, is one of the world’s leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety, effectiveness and ease of use in treating patients with vascular disease. For more information, visit http://www.abbottvascular.com .
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.
Abbott’s news releases and other information are available on the company’s Web site at http://www.abbott.com .
Abbott
CONTACT: Media, Karin Bauer Aranaz, +1-415-859-3414, or Jonathon Hamilton,+1-847-935-8646, or Financial Community, Tina Ventura, +1-847-935-9390, allof Abbott
Company News On-Call: http://www.prnewswire.com/comp/121546.html /
